COUR Pharma
The growth story
COUR Pharma grew from 38 to 59 employees between 2021 and 2026, raising $186M along the way, most recently a Series B in June 2026.
About
COUR is a clinical-stage biotechnology company working to reprogram the immune system to restore health in people suffering from autoimmune diseases. Using our proprietary COUR nanoparticle (CNP) platform for antigen-specific immune tolerance, we develop first-in-class disease-modifying therapies that target disease at its root—without suppressing normal immune system function. With programs in primary biliary cholangitis (PBC), type 1 diabetes (T1D), myasthenia gravis (MG), and celiac disease, COUR is advancing a new standard for immune-modifying therapies.
Founders and leadership
Departments, and which ones grew
Headcount by function: Research 18 (-31% YoY), Business Development 8 (+33% YoY), Operations 8 (-11% YoY), Quality Assurance 6 (-14% YoY), Engineering 4 (-33% YoY), Legal 4 (+33% YoY).
Talent flow
Most common previous employers of COUR Pharma staff: Novartis (7), AbbVie (6), Pfizer (5), Horizon (4), Amgen (4), Northwestern University (4). Former COUR Pharma employees most often moved to AbbVie (6), CatalystBio (2), Amphix Bio (2), BioTechLogic (2), Patient Square Capital (1), CREATE Medicines (1).
Alumni worth knowing
Web traffic
Traffic mix: 0% direct, 0% search, 0% social, 0% paid.
What this company is made of
Most common skills at COUR Pharma: Biotechnology (17), Research Skills (15), Cell Culture (15), Leadership (14), Pharmaceutics (13), Molecular Biology (13), Good Manufacturing Practice (GMP) (13), Project Management (13).
Where the team actually sits
COUR Pharma people are concentrated in Illinois, United States (18), Greater Chicago Area (17), United States (7), Tennessee, United States (2).
Search footprint
COUR Pharma attracts about 280 organic search visits a month, traffic worth roughly $1K a month if bought through ads. It gained 26 ranking keywords and lost 30 in the last period.
What employees say
- Compensation
- 4.20 / 5
- Career opportunities
- 3.00 / 5
- Senior management
- 2.40 / 5
- Work-life balance
- 2.90 / 5
Frequently asked
COUR Pharma has 59 employees as of September 2026.
COUR Pharma has raised $186M in total, most recently a Series B round in June 2026.
The most common previous employers of current COUR Pharma staff are Novartis (7 people), AbbVie (6 people), Pfizer (5 people).
Former COUR Pharma employees most often move to AbbVie (6), CatalystBio (2), Amphix Bio (2).
COUR Pharma attracts about 280 organic search visits a month, worth roughly $1K a month in equivalent ad spend.
The most common skills among COUR Pharma staff are Biotechnology, Research Skills, Cell Culture, Leadership, Pharmaceutics.
COUR Pharma staff are concentrated in Illinois, United States (18), Greater Chicago Area (17), United States (7).
COUR Pharma has about 18 people in Research, down 31% over the past year, as of September 2026.
COUR Pharma has about 8 people in Business Development, up 33% over the past year, as of September 2026.
Computed from 52 current and 79 former COUR Pharma profiles, as of September 2026. Source: Crustdata.
Build this for any company
Every number on this page came from the Crustdata API. Point the MCP at a company and get the same org chart, alumni list and talent flow in one prompt.